Clincosm LogoSign in Get a demo

Role of Magnetic Resonance Imaging (MRI) Perfusion to Detect Disease in Prostate Carcinoma

Sponsor
University Health Network, Toronto (Other)
Overall Status
Completed
CT.gov ID
NCT00230386
Collaborator
Princess Margaret Hospital, Canada (Other)
50
Enrollment
1
Location

Study Details

Study Description

Brief Summary

This is a pilot study of 50 patients to establish whether there is a potential role for MRI perfusion in the detection of locally recurrent or persistent prostate carcinoma after previous treatment with radiotherapy. All subjects will be patients who have had localised prostate cancer treated with radiotherapy and have already agreed to undergo a biopsy of the prostate to look at local control within the prostate as part of their management. The objective of the study is to establish whether there is a relationship between recurrent or persistent disease within the prostate and increased perfusion on MRI at these sites.

Condition or Disease Intervention/Treatment Phase
  • Device: MRI
 Phase 1/Phase 2

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Role of MRI Perfusion to Detect Locally Recurrent or Persistent Disease in Prostate Carcinoma Treated With Radiation Therapy - A Pilot Study
Study Start Date :
May 1, 2003

Outcome Measures

Primary Outcome Measures

  1. To determine whether there may be a role for MRI perfusion in the detection of recurrent or persistent prostatic cancer after previous radiotherapy []

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  • Previously have had radical radiotherapy for localised prostate cancer

  • Due to undergo routine post-treatment prostatic biopsies

  • Suitable for MRI scan

  • Adequate renal function

  • No previous reaction to gadolinium

  • Able to give informed consent

  • No recent prostate biopsy within 6 weeks of enrolment

  • Performance status (Eastern Cooperative Oncology Group [ECOG]) 0 or 1

Exclusion Criteria:

  • Not suitable for MRI scan

  • Previous reaction to gadolinium

  • Impaired renal function

  • Inability to give informed consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Health Network Princess Margaret Hospital Toronto Ontario Canada M5G 2M9

Sponsors and Collaborators

  • University Health Network, Toronto
  • Princess Margaret Hospital, Canada

Investigators

  • Principal Investigator: Michael Milosevic, MD, Princess Margaret Hospital, Canada

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00230386
Other Study ID Numbers:
  • UHN REB 03-0272-CE
First Posted:
Sep 30, 2005
Last Update Posted:
Jul 14, 2009
Last Verified:
Sep 1, 2005
Additional relevant MeSH terms:
Prostatic Neoplasms

Study Results

No Results Posted as of Jul 14, 2009